Mainz Biomed N.V. announced the commencement of the feasibility phase for its PancAlert project, which focuses on developing a non-invasive blood-based screening test for the early detection of pancreatic cancer. This phase aims to confirm the discovery analysis performed in early 2025 with Liquid Biosciences.
The feasibility stage involves testing a panel of selected mRNA biomarkers and the accompanying machine learning-based algorithm in real clinical blood samples, in collaboration with Crown Bioscience. The primary goal is to evaluate the robustness, reproducibility, and diagnostic performance of the assay.
The discovery analysis previously demonstrated a sensitivity of 95% and specificity of 98% for pancreatic cancer detection in blood samples. Subject to the outcome of this feasibility phase, Mainz Biomed intends to proceed with a larger validation study, a critical step towards optimizing the test for clinical utility and potential FDA submission.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.